Lundbeck buys Alder, eyeing migraine drug
Denmark ’s Lundbeck has agreed to buy Alder BioPharmaceuticals in a deal valued at almost $2 billion, hoping to profit from a potential blockbuster migraine drug.
Source: PharmaManufacturing.com - Category: Pharmaceuticals Source Type: news